Human Genome Epidemiology Literature Finder
|
Records 1 - 20 (of 20 Records) |
| Query Trace: Nausea and KRAS[original query] |
|---|
| [Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2009 Nov 12 (6): 594-7. Pu Xing-xiang, Deng Yan-hong, Xu Fei, Xiao Jian, Guo Hong-qiang, Huang He, Tian Ying, He You-jian, Lin Tong- |
| A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Aug 6 (8): 1435-7. Riely Gregory J, Johnson Melissa L, Medina Chanoa, Rizvi Naiyer A, Miller Vincent A, Kris Mark G, Pietanza M Catherine, Azzoli Christopher G, Krug Lee M, Pao William, Ginsberg Michelle |
| A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jun 19 (11): 3068-77. Socinski Mark A, Goldman Jonathan, El-Hariry Iman, Koczywas Marianna, Vukovic Vojo, Horn Leora, Paschold Eugene, Salgia Ravi, West Howard, Sequist Lecia V, Bonomi Philip, Brahmer Julie, Chen Lin-Chi, Sandler Alan, Belani Chandra P, Webb Timothy, Harper Harry, Huberman Mark, Ramalingam Suresh, Wong Kwok-Kin, Teofilovici Florentina, Guo Wei, Shapiro Geoffrey |
| Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. The Lancet. Oncology 2014 May 15 (6): 601-11. Primrose John, Falk Stephen, Finch-Jones Meg, Valle Juan, O'Reilly Derek, Siriwardena Ajith, Hornbuckle Joanne, Peterson Mark, Rees Myrddin, Iveson Tim, Hickish Tamas, Butler Rachel, Stanton Louise, Dixon Elizabeth, Little Louisa, Bowers Megan, Pugh Siân, Garden O James, Cunningham David, Maughan Tim, Bridgewater Jo |
| A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clinical colorectal cancer 2016 Mar . Bowles Daniel W, Kochenderfer Mark, Cohn Allen, Sideris Lucas, Nguyen Nghia, Cline-Burkhardt Vivian, Schnadig Ian, Choi Minsig, Nabell Lisle, Chaudhry Arvind, Ruxer Robert, Ucar Antonio, Hausman Diana, Walker Luke, Spira Alexander, Jimeno Anton |
| A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. British journal of cancer 2017 Feb . Bendell Johanna C, Javle Milind, Bekaii-Saab Tanios S, Finn Richard S, Wainberg Zev A, Laheru Daniel A, Weekes Colin D, Tan Benjamin R, Khan Gazala N, Zalupski Mark M, Infante Jeffrey R, Jones Suzanne, Papadopoulos Kyriakos P, Tolcher Anthony W, Chavira Renae E, Christy-Bittel Janna L, Barrett Emma, Patnaik Ami |
| Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 04 13 (4): 576-584. Felip Enriqueta, Barlesi Fabrice, Besse Benjamin, Chu Quincy, Gandhi Leena, Kim Sang-We, Carcereny Enric, Sequist Lecia V, Brunsvig Paal, Chouaid Christos, Smit Egbert F, Groen Harry J M, Kim Dong-Wan, Park Keunchil, Avsar Emin, Szpakowski Sebastian, Akimov Mikhail, Garon Edward |
| Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study. Cancer research and treatment 2017 1 49 (4): 1022-1032. Woo Sang Myung, Kim Min Kyeong, Joo Jungnam, Yoon Kyong-Ah, Park Boram, Park Sang-Jae, Han Sung-Sik, Lee Ju Hee, Hong Eun Kyung, Kim Yun-Hee, Moon Hae, Kong Sun-Young, Kim Tae Hyun, Lee Woo J |
| An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. Cancer chemotherapy and pharmacology 2018 Jul . Furuse Junji, Kurata Takayasu, Okano Naohiro, Fujisaka Yasuhito, Naruge Daisuke, Shimizu Toshio, Kitamura Hiroshi, Iwasa Tsutomu, Nagashima Fumio, Nakagawa Kazuhi |
| Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 2018 Jun . Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens |
| Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2018 Mar 117 44-49. Gerber David E, Socinski Mark A, Neal Joel W, Wakelee Heather A, Shirai Keisuke, Sequist Lecia V, Rosovsky Rachel P, Lilenbaum Rogerio C, Bastos Bruno R, Huang Chao, Johnson Melissa L, Hesketh Paul J, Subramaniam Deepa S, Dietrich Martin F, Chai Feng, Wang Yunxia, Kazakin Julia, Schwartz Brian, Schiller Joan H, Brahmer Julie R, Kelly Ronan |
| Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 2 36 (13): 1291-1299. Juric Dejan, Rodon Jordi, Tabernero Josep, Janku Filip, Burris Howard A, Schellens Jan H M, Middleton Mark R, Berlin Jordan, Schuler Martin, Gil-Martin Marta, Rugo Hope S, Seggewiss-Bernhardt Ruth, Huang Alan, Bootle Douglas, Demanse David, Blumenstein Lars, Coughlin Christina, Quadt Cornelia, Baselga Jo |
| Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The oncologist 2020 12 26 (4): 290-e545. van Brummelen Emilie M J, Huijberts Sanne, van Herpen Carla, Desar Ingrid, Opdam Frans, van Geel Robin, Marchetti Serena, Steeghs Neeltje, Monkhorst Kim, Thijssen Bas, Rosing Hilde, Huitema Alwin, Beijnen Jos, Bernards Rene, Schellens J |
| Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Jan . Dhani Neesha C, Hirte Hal W, Wang Lisa, Burnier Julia V, Jain Angela, Butler Marcus O, Welch Stephen, Fleming Gini F, Hurteau Jean, Matsuo Koji, Matei Daniela, Jimenez Waldo, Johnston Carolyn, Cristea Mihaela, Tonkin Katia, Ghatage Prafull, Lheureux Stephanie, Mehta Anjali, Quintos Judy, Tan Qian, Kamel-Reid Suzanne, Ludkovski Olga, Tsao Ming-Sound, Wright John J, Oza Amit |
| Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO precision oncology 2022 2 6 e2100424. Krop Ian E, Jegede Opeyemi A, Grilley-Olson Juneko E, Lauring Josh D, Mitchell Edith P, Zwiebel James A, Gray Robert J, Wang Victoria, McShane Lisa M, Rubinstein Larry V, Patton David, Williams P Mickey, Hamilton Stanley R, Kono Scott A, Ford James M, Garcia Agustin A, Sui Xingwei D, Siegel Robert D, Slomovitz Brian M, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith |
| RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer. Biomedicines 2023 5 11 (5): . Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouz |
| Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042). Clinical cancer research : an official journal of the American Association for Cancer Research 2023 5 . Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Gregory J Gerstner, Timothy F Burns, Asma Taj, Wallace L Akerley, Konstantin H Dragnev, Noel Laudi, Mary W Redman, Jhanelle E Gray, David R Gandara, Karen Kel |
| Efficacy and toxicity of drugs targeting KRAS mutation in non-small cell lung cancer: a meta-analysis. Expert review of anticancer therapy 2023 11 . Wei Luo, Jing Zhu, Wenxue Zhang, Airu Yu, Wei Zhou, Ke |
| Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC. European journal of cancer (Oxford, England : 1990) 2024 7 208 114204. Maximilian J Hochmair, Karim Vermaelen, Giannis Mountzios, Enric Carcereny, Christophe Dooms, Se-Hoon Lee, Eva Morocz, Terufumi Kato, Tudor-Eliade Ciuleanu, Grace K Dy, Barbara Parente, Kenneth J O'Byrne, Quincy S Chu, Gilberto De Castro Junior, Nicolas Girard, Wendy Snyder, Qui Tran, William Kormany, Brett Houk, Bhakti Mehta, Alessandra Curioni-Fonteced |
| TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice. Frontiers in oncology 2024 10 14 1450732. Ji Eun Shin, Sung Hee Lim, Jeeyun Lee, Ho Yeong Lim, Young Suk Park, Seung Tae K |
- Page last reviewed:Feb 1, 2024
- Content source: